TRRI — Alzex Neuropharma Income Statement
0.000.00%
Last trade - 00:00FinancialsHighly SpeculativeMicro Cap
- $0.15m
- $0.21m
Annual income statement for Alzex Neuropharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2011 December 31st | 2012 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PRESS | ARS |
| Standards: | — | — |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 0.01 | 0 |
| Cost of Revenue | ||
| Gross Profit | -0.003 | 0 |
| Selling / General / Administrative Expenses | ||
| Depreciation and Amortization | ||
| Total Operating Expenses | 0.076 | 0.031 |
| Operating Profit | -0.067 | -0.031 |
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -0.075 | -0.038 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -0.075 | -0.038 |
| Net Income Before Extraordinary Items | ||
| Net Income | -0.075 | -0.038 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Dilution Adjustment | ||
| Diluted Net Income | -0.075 | -0.038 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.061 | -0 |
| Dividends per Share |